Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

Stock Information for Matinas Biopharma Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.